References
- Buchan P, et al. Pharmacokinetics of frovatriptan (VML251/SB209509) in male and female subjects. Funct Neurol 1998;13:BC3, 177
- Buchan P, et al. Interactions of frovatriptan and its desmethyl derivative with monoamine oxidase. Abstract 4 th EFNS Congress, Lisbon, Portugal, September 7–11 1999
- Buchan P, et al. Lack of interaction between frovatriptan and the monoamine oxidase inhibitor, moclobermide. Cephalalgia 1999;19:II – G1–30
- Data on file
- Buchan P, et al. The effect of propranolol on the pharmaco-kinetic and safety profiles of frovatriptan. Cephalalgia 1999;19:II – G1–32
- Buchan P, et al. Lack of clinically significant interactions between frovatriptan and ergotamine. Cephalalgia 1999; 19:II – G1–31
- Data on file
- Goldstein J, Keywood C. A low dose range finding study of frovatriptan (VML 251) a potent selective 5HT1B/1D receptor agonist for the acute treatment of migraine. Funct Neurol 1998: 13:BC7, 178
- Ryan R, Keywood C. A preliminary study of VML251 (SB209509) a novel 5HT1B/1D receptor agonist for the acute treatment of migraine. Eur J Neurol 1998;5 (Suppl 3): S46
- Keywood C. The effects of ascending doses of oral frovatriptan (VML251/SB 209509), a potent selective 5HT1B/1D receptor agonist for the acute treatment of migraine, on the cardiovascular system of healthy male volunteers. Headache 1998;38:388
- MacDaris HL, Hutchison J. Frovatriptan – a review of overall clinical efficacy. Cephalalgia 1999;19:II – G1–29
- Spierings EHL, Hutchison J. Frovatriptan – a review of safety and tolerability. Cephalalgia 1999;19:II – G1–41
- Elkind A, McDaris HL, Satin L, Keywood C. The cardiovascular safety of frovatriptan in patients at high risk of or with known coronary artery disease, during a migraine attack. Cephalalgia 1999;19:II – G1–35